BR112023017808A2 - Terapia genética de hb-egf para diabetes - Google Patents
Terapia genética de hb-egf para diabetesInfo
- Publication number
- BR112023017808A2 BR112023017808A2 BR112023017808A BR112023017808A BR112023017808A2 BR 112023017808 A2 BR112023017808 A2 BR 112023017808A2 BR 112023017808 A BR112023017808 A BR 112023017808A BR 112023017808 A BR112023017808 A BR 112023017808A BR 112023017808 A2 BR112023017808 A2 BR 112023017808A2
- Authority
- BR
- Brazil
- Prior art keywords
- diabetes
- growth factor
- gene therapy
- relates
- present
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 4
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 title abstract 3
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 title abstract 3
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 101000871708 Homo sapiens Proheparin-binding EGF-like growth factor Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100033762 Proheparin-binding EGF-like growth factor Human genes 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021033714 | 2021-03-03 | ||
| JP2021145796 | 2021-09-07 | ||
| PCT/JP2022/008898 WO2022186282A1 (ja) | 2021-03-03 | 2022-03-02 | 糖尿病に対するｈｂ－ｅｇｆ遺伝子治療 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017808A2 true BR112023017808A2 (pt) | 2023-09-26 |
Family
ID=83154306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017808A BR112023017808A2 (pt) | 2021-03-03 | 2022-03-02 | Terapia genética de hb-egf para diabetes |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240173381A1 (https=) |
| EP (1) | EP4302785A4 (https=) |
| JP (1) | JPWO2022186282A1 (https=) |
| KR (1) | KR20240004273A (https=) |
| AU (1) | AU2022230492A1 (https=) |
| BR (1) | BR112023017808A2 (https=) |
| CA (1) | CA3212726A1 (https=) |
| IL (1) | IL305627A (https=) |
| MX (1) | MX2023010315A (https=) |
| PH (1) | PH12023552425A1 (https=) |
| WO (1) | WO2022186282A1 (https=) |
| ZA (1) | ZA202309227B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2025211357A1 (https=) * | 2024-04-02 | 2025-10-09 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1949907B1 (en) * | 2005-09-28 | 2014-07-02 | Kagoshima University | Novel application of heparin-binding epidermal growth factor-like growth factor for medical purposes |
| JP2007223939A (ja) * | 2006-02-22 | 2007-09-06 | Kobe Univ | エネルギー代謝促進因子としてのｈｂ−ｅｇｆの使用 |
| US8236758B2 (en) * | 2007-07-20 | 2012-08-07 | Saitama Medical University | Method of treatment of diabestes or reduction in pancreatic beta-cells |
| JP6711495B1 (ja) | 2019-05-27 | 2020-06-17 | 株式会社ナイスリー | 車両用盗難防止装置 |
| JP2021033714A (ja) | 2019-08-26 | 2021-03-01 | 東芝テック株式会社 | 商品販売データ処理装置及びプログラム |
| JP7040807B2 (ja) | 2020-03-17 | 2022-03-23 | 株式会社オリンピア | 遊技機 |
-
2022
- 2022-03-02 AU AU2022230492A patent/AU2022230492A1/en active Pending
- 2022-03-02 BR BR112023017808A patent/BR112023017808A2/pt unknown
- 2022-03-02 PH PH1/2023/552425A patent/PH12023552425A1/en unknown
- 2022-03-02 JP JP2023503916A patent/JPWO2022186282A1/ja active Pending
- 2022-03-02 CA CA3212726A patent/CA3212726A1/en active Pending
- 2022-03-02 US US18/548,807 patent/US20240173381A1/en active Pending
- 2022-03-02 KR KR1020237033566A patent/KR20240004273A/ko active Pending
- 2022-03-02 IL IL305627A patent/IL305627A/en unknown
- 2022-03-02 WO PCT/JP2022/008898 patent/WO2022186282A1/ja not_active Ceased
- 2022-03-02 MX MX2023010315A patent/MX2023010315A/es unknown
- 2022-03-02 EP EP22761939.2A patent/EP4302785A4/en active Pending
-
2023
- 2023-10-02 ZA ZA2023/09227A patent/ZA202309227B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4302785A1 (en) | 2024-01-10 |
| PH12023552425A1 (en) | 2024-02-19 |
| CA3212726A1 (en) | 2022-09-09 |
| JPWO2022186282A1 (https=) | 2022-09-09 |
| KR20240004273A (ko) | 2024-01-11 |
| IL305627A (en) | 2023-11-01 |
| MX2023010315A (es) | 2023-11-24 |
| WO2022186282A1 (ja) | 2022-09-09 |
| US20240173381A1 (en) | 2024-05-30 |
| ZA202309227B (en) | 2024-06-26 |
| EP4302785A4 (en) | 2025-01-29 |
| AU2022230492A1 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3482768T3 (fi) | Menetelmiä ja kittejä infuusioreaktioriskin ja vasteen vasta-ainevälitteisen häviämisen ehkäisemiseksi seerumin virtsahappoa monitoroimalla pegyloidulla urikaasilla tehtävän hoidon aikana | |
| BR112022019501A2 (pt) | Construção de rna auto-amplificante (sarna), sarna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de sarna, construção de sarna e vacina | |
| BR112023017808A2 (pt) | Terapia genética de hb-egf para diabetes | |
| MX2023007574A (es) | "vacuna de arn contra variantes de sars-cov-2. | |
| Moriondo et al. | Proteoglycan fragmentation and respiratory mechanics in mechanically ventilated healthy rats | |
| ES2770113T3 (es) | Análogos de la cisteamina resistentes a la ADO y sus usos | |
| MX2021005560A (es) | Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l). | |
| Mang et al. | Awake extracorporeal membrane oxygenation for COVID-19–induced acute respiratory distress syndrome | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| Sharma et al. | Endotracheal intubation through the intubating laryngeal mask airway (LMA-Fastrach™): A randomized study of LMA-Fastrach™ wire-reinforced silicone endotracheal tube versus conventional polyvinyl chloride tracheal tube | |
| Lan et al. | Influence of lateral position and pneumoperitoneum on oropharyngeal leak pressure with two types of laryngeal mask airways | |
| Zaballos et al. | Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial | |
| WO2022177742A3 (en) | Tirzepatide therapeutic methods | |
| Kako et al. | Changes in intracuff pressure of a cuffed endotracheal tube during surgery for congenital heart disease using cardiopulmonary bypass | |
| Amos et al. | Survival following traumatic thoracic compartment syndrome managed with VV-ECMO | |
| Cho et al. | Anesthetic management of a patient with glucose-6-phosphate dehydrogenase deficiency undergoing robot-assisted laparoscopic surgery-A case report | |
| Jeong et al. | Effect-site concentration of remifentanil for minimizing cardiovascular changes by inhalation of desflurane | |
| Göktaş et al. | Dexmedetomidine and Fentanyl in Endotracheal Intubation: A Comparative Analysis of Hemodynamic and Intubation Responses | |
| Perilli et al. | Carbon dioxide absorption during retroperitoneoscopic adrenalectomy: comparison between monolateral and synchronous bilateral approaches | |
| BR112022009522A2 (pt) | Métodos de administração de voxelotor | |
| Yue et al. | Clinical observations of high-flow nasal cannula oxygenation in endobronchial ultrasound-guided transbronchial needle aspiration: a randomized controlled study | |
| Cao | High-flow nasal cannula versus nasal cannula for advanced bronchoscopy | |
| Kücükosman et al. | The Effects of Intraoperative Oxygen used at Different Concentrations on Oxidative Stress Markers: A Randomized Prospective Study | |
| Mishra | Comparative hemodynamic efficacy of intubating LMA Fastrach and Ambu Aura− I as a conduit for intubation during general anaesthesia in adult: a randomized, clinical study | |
| Szmuk et al. | CobraPLA as a conduit for flexible bronchoscopy in a child under general anaesthesia |